Att sitta i samma båt- En litteraturstudie om cancerpatienters upplevelser av stödgrupper och självhjälpsgrupper

Varje år upptäcks 50 000 nya fall av cancer i Sverige, vilket innebär att drygt 100 personer insjuknar varje dag. Att få diagnosen cancer innebär ofta en chock för den drabbade. Det sociala stödet är av stor betydelse för hur krisen kommer att hanteras av patienten. Syftet med litteraturstudien var att kartlägga cancerpatienters upplevelser av att delta i olika former av stödgrupper och självhjälpsgrupper som kan ledas eller initieras av sjuksköterskan. Metoden är en litteraturstudie utförd på tio kvalitativa artiklar. Som teoretisk referensram har Travelbees omvårdnadsteori använts. Resultatet visade att stödgrupper eller självhjälpsgrupper gav upplevelsen av att känna gemenskap och tillhörighet mellan deltagarna, att få och ge stöd av varandra, stärkt självförtroende, att uppleva hopp samt negativa upplevelser av deltagande.Each year 50 000 new cases of cancer in Sweden is discovered, which means that more than 100 people is diagnosed every day. Getting diagnosed with cancer is often a shock to the victim. Social support is of great importance for how the crisis will be handled by the patient. The aim of the literature review was to identify cancer patients' experiences of participation in various forms of support and self-help groups that can be led or initiated by a nurse. The method is a literature review conducted in ten qualitative articles. As a theoretical framework Travelbees nursing theory has been used. The results showed that support groups or self-help groups gave the experience of a feeling of fellowship and belonging among the participants, to get and give support to each other, stronger self-confidence, to feel hopeful and negative experiences of participation

Att sitta i samma båt- En litteraturstudie om cancerpatienters upplevelser av stödgrupper och självhjälpsgrupper

Varje år upptäcks 50 000 nya fall av cancer i Sverige, vilket innebär att drygt 100 personer insjuknar varje dag. Att få diagnosen cancer innebär ofta en chock för den drabbade. Det sociala stödet är av stor betydelse för hur krisen kommer att hanteras av patienten. Syftet med litteraturstudien var att kartlägga cancerpatienters upplevelser av att delta i olika former av stödgrupper och självhjälpsgrupper som kan ledas eller initieras av sjuksköterskan. Metoden är en litteraturstudie utförd på tio kvalitativa artiklar. Som teoretisk referensram har Travelbees omvårdnadsteori använts. Resultatet visade att stödgrupper eller självhjälpsgrupper gav upplevelsen av att känna gemenskap och tillhörighet mellan deltagarna, att få och ge stöd av varandra, stärkt självförtroende, att uppleva hopp samt negativa upplevelser av deltagande.Each year 50 000 new cases of cancer in Sweden is discovered, which means that more than 100 people is diagnosed every day. Getting diagnosed with cancer is often a shock to the victim. Social support is of great importance for how the crisis will be handled by the patient. The aim of the literature review was to identify cancer patients' experiences of participation in various forms of support and self-help groups that can be led or initiated by a nurse. The method is a literature review conducted in ten qualitative articles. As a theoretical framework Travelbees nursing theory has been used. The results showed that support groups or self-help groups gave the experience of a feeling of fellowship and belonging among the participants, to get and give support to each other, stronger self-confidence, to feel hopeful and negative experiences of participation

Chromosome 19 Annotations with Disease Speciation: A First Report from the Global Research Consortium

A first research development progress report of the Chromosome 19 Consortium with members from Sweden, Norway, Spain, United States, China and India, a part of the Chromosome-centric Human Proteome Project (C-HPP) global initiative, is presented (http://www.c-hpp.org). From the chromosome 19 peptide-targeted library constituting 6159 peptides, a pilot study was conducted using a subset with 125 isotope-labeled peptides. We applied an annotation strategy with triple quadrupole, ESI-Qtrap, and MALDI mass spectrometry platforms, comparing the quality of data within and in between these instrumental set-ups. LC–MS conditions were outlined by multiplex assay developments, followed by MRM assay developments. SRM was applied to biobank samples, quantifying kallikrein 3 (prostate specific antigen) in plasma from prostate cancer patients. The antibody production has been initiated for more than 1200 genes from the entire chromosome 19, and the progress developments are presented. We developed a dedicated transcript microarray to serve as the mRNA identifier by screening cancer cell lines. NAPPA protein arrays were built to align with the transcript data with the Chromosome 19 NAPPA chip, dedicated to 90 proteins, as the first development delivery. We have introduced an IT-infrastructure utilizing a LIMS system that serves as the key interface for the research teams to share and explore data generated within the project. The cross-site data repository will form the basis for sample processing, including biological samples as well as patient samples from national Biobanks

Chromosome 19 Annotations with Disease Speciation: A First Report from the Global Research Consortium

A first research development progress report of the Chromosome 19 Consortium with members from Sweden, Norway, Spain, United States, China and India, a part of the Chromosome-centric Human Proteome Project (C-HPP) global initiative, is presented (http://www.c-hpp.org). From the chromosome 19 peptide-targeted library constituting 6159 peptides, a pilot study was conducted using a subset with 125 isotope-labeled peptides. We applied an annotation strategy with triple quadrupole, ESI-Qtrap, and MALDI mass spectrometry platforms, comparing the quality of data within and in between these instrumental set-ups. LC–MS conditions were outlined by multiplex assay developments, followed by MRM assay developments. SRM was applied to biobank samples, quantifying kallikrein 3 (prostate specific antigen) in plasma from prostate cancer patients. The antibody production has been initiated for more than 1200 genes from the entire chromosome 19, and the progress developments are presented. We developed a dedicated transcript microarray to serve as the mRNA identifier by screening cancer cell lines. NAPPA protein arrays were built to align with the transcript data with the Chromosome 19 NAPPA chip, dedicated to 90 proteins, as the first development delivery. We have introduced an IT-infrastructure utilizing a LIMS system that serves as the key interface for the research teams to share and explore data generated within the project. The cross-site data repository will form the basis for sample processing, including biological samples as well as patient samples from national Biobanks

Chromosome 19 Annotations with Disease Speciation: A First Report from the Global Research Consortium

A first research development progress report of the Chromosome 19 Consortium with members from Sweden, Norway, Spain, United States, China and India, a part of the Chromosome-centric Human Proteome Project (C-HPP) global initiative, is presented (http://www.c-hpp.org). From the chromosome 19 peptide-targeted library constituting 6159 peptides, a pilot study was conducted using a subset with 125 isotope-labeled peptides. We applied an annotation strategy with triple quadrupole, ESI-Qtrap, and MALDI mass spectrometry platforms, comparing the quality of data within and in between these instrumental set-ups. LC–MS conditions were outlined by multiplex assay developments, followed by MRM assay developments. SRM was applied to biobank samples, quantifying kallikrein 3 (prostate specific antigen) in plasma from prostate cancer patients. The antibody production has been initiated for more than 1200 genes from the entire chromosome 19, and the progress developments are presented. We developed a dedicated transcript microarray to serve as the mRNA identifier by screening cancer cell lines. NAPPA protein arrays were built to align with the transcript data with the Chromosome 19 NAPPA chip, dedicated to 90 proteins, as the first development delivery. We have introduced an IT-infrastructure utilizing a LIMS system that serves as the key interface for the research teams to share and explore data generated within the project. The cross-site data repository will form the basis for sample processing, including biological samples as well as patient samples from national Biobanks

Chromosome 19 Annotations with Disease Speciation: A First Report from the Global Research Consortium

A first research development progress report of the Chromosome 19 Consortium with members from Sweden, Norway, Spain, United States, China and India, a part of the Chromosome-centric Human Proteome Project (C-HPP) global initiative, is presented (http://www.c-hpp.org). From the chromosome 19 peptide-targeted library constituting 6159 peptides, a pilot study was conducted using a subset with 125 isotope-labeled peptides. We applied an annotation strategy with triple quadrupole, ESI-Qtrap, and MALDI mass spectrometry platforms, comparing the quality of data within and in between these instrumental set-ups. LC–MS conditions were outlined by multiplex assay developments, followed by MRM assay developments. SRM was applied to biobank samples, quantifying kallikrein 3 (prostate specific antigen) in plasma from prostate cancer patients. The antibody production has been initiated for more than 1200 genes from the entire chromosome 19, and the progress developments are presented. We developed a dedicated transcript microarray to serve as the mRNA identifier by screening cancer cell lines. NAPPA protein arrays were built to align with the transcript data with the Chromosome 19 NAPPA chip, dedicated to 90 proteins, as the first development delivery. We have introduced an IT-infrastructure utilizing a LIMS system that serves as the key interface for the research teams to share and explore data generated within the project. The cross-site data repository will form the basis for sample processing, including biological samples as well as patient samples from national Biobanks

Chromosome 19 annotations with disease speciation: a first report from the Global Research Consortium.

A first research development progress report of the Chromosome 19 Consortium with members from Sweden, Norway, Spain, United States, China and India, a part of the Chromosome-centric Human Proteome Project (C-HPP) global initiative, is presented ( http://www.c-hpp.org ). From the chromosome 19 peptide-targeted library constituting 6159 peptides, a pilot study was conducted using a subset with 125 isotope-labeled peptides. We applied an annotation strategy with triple quadrupole, ESI-Qtrap, and MALDI mass spectrometry platforms, comparing the quality of data within and in between these instrumental set-ups. LC-MS conditions were outlined by multiplex assay developments, followed by MRM assay developments. SRM was applied to biobank samples, quantifying kallikrein 3 (prostate specific antigen) in plasma from prostate cancer patients. The antibody production has been initiated for more than 1200 genes from the entire chromosome 19, and the progress developments are presented. We developed a dedicated transcript microarray to serve as the mRNA identifier by screening cancer cell lines. NAPPA protein arrays were built to align with the transcript data with the Chromosome 19 NAPPA chip, dedicated to 90 proteins, as the first development delivery. We have introduced an IT-infrastructure utilizing a LIMS system that serves as the key interface for the research teams to share and explore data generated within the project. The cross-site data repository will form the basis for sample processing, including biological samples as well as patient samples from national Biobanks